https://visiomed.ai/en/news VisioMed.AI news: regulatory milestones, partnerships, competitions and platform updates for AI-based OCT and fundus image analysis. en https://visiomed.ai/en/news/moscow-startup-summit-2026 https://visiomed.ai/en/news/moscow-startup-summit-2026 Sat, 26 Sep 2026 21:00:00 GMT As a Sber500 participant, VisioMed.AI will take part in the Moscow Startup Summit on September 29–30. Ilya Kovrizhnyh will present our solution at the pitch session. At the VisioMed.AI booth, anyone can get a vision check-up, run by a physician from the Helmholtz National Medical Research Center of Eye Diseases using the VisioMed.AI platform. https://visiomed.ai/en/news/roof-2026-oct-ai https://visiomed.ai/en/news/roof-2026-oct-ai Thu, 24 Sep 2026 21:00:00 GMT At the XIX Russian National Ophthalmological Forum (ROOF 2026, Moscow, September 23–25), O. V. Zaytseva of the Helmholtz National Medical Research Center of Eye Diseases presented a joint talk with VisioMed.AI, “Artificial intelligence in macular OCT interpretation”. Authors: O. V. Zaytseva, A. T. Khandzhyan, N. V. Neroeva (Helmholtz Center), I. A. Kovrizhnyh, M. K. Kulyabin, A. E. Zhdanov (VisioMed.AI). The talk reviewed AI systems for OCT analysis in Russia and abroad. All of them detect biomarkers and return a list of likely diagnoses, but none produces a full structured description of the scan. That is what our module does: a description of each biomarker with its measurements, their clinical interpretation, and a conclusion with a suggested diagnosis and ICD-10 code, ready for a physician to verify. At its core are two independent neural analyses of the same scan. The segmentation model finds 16 biomarkers and measures their area, size and number of lesions. The classification model assigns the scan to 14 classes (13 diseases and conditions plus normal), and one scan can match several classes at once. A clinical weight matrix brings the two together: each biomarker either supports a diagnosis or counts against it, while the classifier adds at most four points and cannot make a diagnosis on its own. For a full-thickness macular hole, morphometry and standardized indices are calculated automatically. In a pilot study, automated reports for 108 de-identified OCT scans were each assessed independently by two Helmholtz Center experts with at least ten years of OCT experience. Full agreement with the expert interpretation was reached in 75.9% of cases (82 of 108), full or partial agreement in 93.5% (101 of 108). Partial meant the leading pathology was right but secondary biomarkers were described incompletely. These are pilot data; the results are being prepared for publication. Next come more biomarkers and conditions, segmentation of retinal layers, a unified OCT reporting protocol, and assessment of indications for anti-VEGF therapy. Automated interpretation remains a supporting tool: the decision always rests with the physician. https://visiomed.ai/en/news/sber500-batch7-top25 https://visiomed.ai/en/news/sber500-batch7-top25 Wed, 26 Aug 2026 21:00:00 GMT VisioMed.AI has completed the Bootcamp of Sber500 Batch 7 and is among the 25 startups selected for the program's acceleration stage, out of more than 1,800 applications. Next up: working with Sber's mentors and experts to grow the business and its key metrics, preparing the pitch, and a chance to present at Demo Day at the Moscow Startup Summit. The acceleration stage kicks off on September 3. https://visiomed.ai/en/news/yandex-ai-startup-lab-2026 https://visiomed.ai/en/news/yandex-ai-startup-lab-2026 Tue, 28 Apr 2026 21:00:00 GMT Yandex has announced the results of Yandex AI Startup Lab, its accelerator for deep-tech startups: out of roughly a thousand applications from students and graduates of 146 universities, 12 teams reached the final. VisioMed.AI placed second in the DeepTech track, winning 2 million rubles and a 500,000-ruble Yandex Cloud grant. Over the three-month program we ran pilots of our retinal imaging analysis at clinics in Moscow and the regions, including the Helmholtz National Medical Research Center of Eye Diseases.